What is Lifesci Capital's Estimate for GPCR FY2024 Earnings?

Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) - Lifesci Capital boosted their FY2024 EPS estimates for shares of Structure Therapeutics in a report released on Wednesday, November 13th. Lifesci Capital analyst M. Belghiti now expects that the company will post earnings of ($0.75) per share for the year, up from their prior forecast of ($0.87). The consensus estimate for Structure Therapeutics' current full-year earnings is ($0.80) per share. Lifesci Capital also issued estimates for Structure Therapeutics' Q4 2024 earnings at ($0.19) EPS, Q1 2025 earnings at ($0.18) EPS, Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.22) EPS and FY2025 earnings at ($0.82) EPS.

GPCR has been the subject of a number of other reports. Cantor Fitzgerald reissued an "overweight" rating and set a $65.00 target price on shares of Structure Therapeutics in a research note on Monday, September 23rd. Morgan Stanley initiated coverage on shares of Structure Therapeutics in a report on Monday, September 23rd. They issued an "overweight" rating and a $118.00 target price on the stock. Finally, JMP Securities cut their price target on shares of Structure Therapeutics from $91.00 to $86.00 and set a "market outperform" rating on the stock in a report on Friday, August 9th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Structure Therapeutics has a consensus rating of "Buy" and a consensus price target of $86.80.

Structure Therapeutics Trading Down 7.1 %

Structure Therapeutics stock traded down $2.42 during midday trading on Monday, reaching $31.75. 2,086,598 shares of the stock traded hands, compared to its average volume of 782,447. The firm has a fifty day moving average price of $39.38 and a two-hundred day moving average price of $39.80. The firm has a market cap of $1.82 billion, a price-to-earnings ratio of -42.77 and a beta of -3.23. Structure Therapeutics has a fifty-two week low of $26.61 and a fifty-two week high of $66.38.

Institutional Trading of Structure Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Sandia Investment Management LP acquired a new stake in shares of Structure Therapeutics in the second quarter worth $39,000. Assetmark Inc. raised its stake in Structure Therapeutics by 120.0% during the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company's stock valued at $58,000 after purchasing an additional 719 shares during the last quarter. Quarry LP acquired a new position in shares of Structure Therapeutics in the 2nd quarter valued at $79,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Structure Therapeutics by 60.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company's stock valued at $158,000 after buying an additional 1,420 shares in the last quarter. Finally, Dearborn Partners LLC acquired a new position in shares of Structure Therapeutics in the 3rd quarter valued at $202,000. 91.78% of the stock is owned by institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.